Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study

Florentia Dimitriou; Kenjiro Namikawa; Irene L. M. Reijers; Elizabeth I. Buchbinder; J. Soon; Anne Zaremba; Paweł Teterycz; Meghan J. Mooradian; Emma Armstrong; Yasuhiro Nakamura; Maria Grazia Vitale; Lena Tran; Xue Bai; Clara Allayous; S. Provent-Roy; Alice Indini; Prachi Bhave; Mohamad Farid; Katharina C. Kähler; Inderjit Mehmi; Victoria Atkinson; Oliver Klein; Connor J. Stonesifer; Farzana Y. Zaman; Andrew Haydon; Richard D. Carvajal; Omid Hamid; Reinhard Dummer; Axel Hauschild; Matteo S. Carlino; Mario Mandalà; Caroline Robert; Célèste Lebbé; Jun Guo; Douglas B. Johnson; Paolo A. Ascierto; Alexander N. Shoushtari; Ryan J. Sullivan; Bożena Cybulska-Stopa; Piotr Rutkowski; Lisa Zimmer; Shahneen Sandhu; Christian U. Blank; Serigne Lo; Alexander M. Menzies; Georgina V. Long

doi:10.1016/j.annonc.2022.06.004

Related publications

Article2021

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

Inês Pires da Silva, Tasnia Ahmed, Irene L. M. Reijers, Alison M. Weppler, Allison Betof Warner, James R. Patrinely, Patricio Serra-Bellver, Clara Allayous, Joanna Mangana, Khang Nguyen, Lisa Zimmer, Claudia Trojaniello, Dan Stout, Megan Lyle, Oliver Klein, Camille L. Gérard, Olivier Michielin, Andrew Haydon, Paolo A. Ascierto, Matteo S. Carlino, Célèste Lebbé, Paul Lorigan, Douglas B. Johnson, Shahneen Sandhu, Serigne Lo, Christian U. Blank, Alexander M. Menzies, Georgina V. Long

Article2016

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

Alexander M. Menzies, Douglas B. Johnson, Sangeetha Ramanujam, Victoria Atkinson, Annie Wong, John Park, Jennifer L. McQuade, Alexander N. Shoushtari, Katy K. Tsai, Zeynep Eroglu, Oliver Klein, Jessica C. Hassel, Jeffrey A. Sosman, Alexander Guminski, Ryan J. Sullivan, Antoni Ribas, Matteo S. Carlino, Michael A. Davies, Shahneen Sandhu, Georgina V. Long

Article2016

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders (AD) or major toxicity with ipilimumab (IPI).

Alexander M. Menzies, Douglas B. Johnson, Sangeetha Ramanujam, Victoria Atkinson, Annie Wong, John Park, Jennifer L. McQuade, Alexander N. Shoushtari, Katy K. Tsai, Zeynep Eroglu, Oliver Klein, Jessica C. Hassel, Jeffrey A. Sosman, Alex Guminski, Ryan J. Sullivan, Antoni Ribas, Matteo S. Carlino, Michael A. Davies, Shahneen Sandhu, Georgina V. Long

Article2019

Clinical models to predict response and survival in metastatic melanoma (MM) patients (pts) treated with anti-PD-1 alone (PD1) or combined with ipilimumab (IPI+PD1).

Ines Esteves Domingues Pires Da Silva, Tasnia Ahmed, Serigne Lo, Rajat Rai, Jessica L. Smith, John Park, C. Nabhan, Richard A Scolyer, Matteo S. Carlino, Jennifer L. McQuade, Douglas B. Johnson, Georgina V. Long, Alexander M. Menzies

Article2021

Patterns and management of progression on first-line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patients.

Inês Pires da Silva, Judith M. Versluis, Tasnia Ahmed, Douglas B. Johnson, J. Soon, Clara Allayous, Camille L. Gérard, Joanna Mangana, Oliver Klein, Lisa Zimmer, Caroline Robert, Maria Grazia Vitale, Hui‐Ling Yeoh, Olivier Michielin, Célèste Lebbé, Shahneen Sandhu, Christian U. Blank, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long